The Sensitivity and Specificity of Estrogen Receptor, Progesterone Receptor and HER-2 Staining in Core Biopsies of Invasive Breast Carcinomas

Background: Now a day's determination of estrogen receptor (ER), progesterone receptor (PR) and HER-2/neu expression pattern by immunohistochemistry in invasive breast cancer have become the standard procedure for breast cancer management.Objective: To see the expression pattern of estrogen receptor, progesterone receptor and HER-2/neu in Bangladeshi women with invasive breast carcinoma.Method: This cross sectional study was performed in 87 cases of invasive breast cancer. Estrogen receptor (ER), Progesterone receptor (PR) and HER-2/neu expression pattern were assessed by immunohistochemistry using monoclonal antibodies for detecting estrogen and progesterone receptors, and polyclonal antibody for detecting HER-2/neu.Results: All the cases were graded according to Bloom-Richardson grading system. Of those, Grade I tumour was 18 (20.69%), Grade II tumour was 58 (66.67%) and Grade III tumour was 11(12.64%). Both ER and PR positive reactivity were same and it was found 65 (74.71%) and HER-2/neu reactivity pattern were found negative in 59 (67.82%) cases and positive in 28 (32.18%) cases. A statistically significant correlation was found between the expression of ER and low grade tumour (p=0.011) and combined estrogen and progesterone receptor positive reactivity with low grade tumour (p=0.002).Conclusion: ER, PR and HER-2/neu expression do not correlated with each other, so it is recommended that each test should be independently determined by immunohistochemistry in all cases of invasive breast cancer. All equivocal cases of HER-2/neu (score 2+) should be analyzed by FISH technique to find out the percentage of real score.KYAMC Journal Vol. 5, No.-1, Jul 2014, Page 436-443

Download Full-text

Evaluation of Biomarkers in Multiple Ipsilateral Synchronous Invasive Breast Carcinomas

Archives of Pathology & Laboratory Medicine ◽

10.5858/arpa.2017-0494-oa ◽

2018 ◽

Vol 143 (2) ◽

pp. 190-196

Author(s):

Pooja Navale ◽

Ira J. Bleiweiss ◽

Shabnam Jaffer ◽

Anupma Nayak

Keyword(s):

New York ◽

Progesterone Receptor ◽

Mount Sinai Hospital ◽

Breast Carcinomas ◽

Tumor Focus ◽

Biomarker Testing ◽

Major Variation ◽

Index Tumor ◽

Invasive Breast Carcinomas ◽

Additional Tumor

Context.— The College of American Pathologists guidelines recommend testing additional tumor foci in multifocal invasive breast carcinomas for the biomarkers estrogen receptor (ER), progesterone receptor, and HER2 only if the carcinomas show different morphologies or grades. Objective.— To assess clinical significance of testing for biomarkers in additional tumor foci in multifocal invasive breast tumors. Design.— Retrospective analysis of 118 patients diagnosed with ipsilateral synchronous multifocal breast carcinomas from January 2015 through March 2016 at Mount Sinai Hospital (New York, New York). Results.— Eighty-six cases were tested for at least 1 of the 3 biomarkers in additional tumor foci. Fifteen cases (17%) showed discordant staining between the 2 foci for at least one biomarker. Of the 7 of 67 ER-discordant cases (10%), 4 (57%) showed major variation from negative to positive expression, including 3 cases in which a smaller tumor focus was strongly positive for ER whereas the index tumor was negative. Similarly, within the 7 of 67 progesterone receptor–discordant cases (10%), 4 (57%) showed major variation from negative to positive, and in 3 cases with major discordance, the index tumor was negative for progesterone receptor, whereas a smaller focus was positive. A difference in HER2 expression was noted in 5 of 86 cases (6%). In only 5 of the 15 patients (33%) with discordant results, biomarker testing on additional foci would have been offered per the College of American Pathologists recommendations because of differences in histology or grading. Of the remaining 10 patients, 7 (70%) with positive results on smaller foci would have been deprived of appropriate adjuvant systemic treatment if the smaller focus had not been tested. Conclusions.— We propose that negative values expressed in the primary tumor be repeated routinely on additional ipsilateral synchronous tumors.

Download Full-text

Estrogen Receptor, Progesterone Receptor, and HER-2 Negative

Encyclopedia of Cancer ◽

10.1007/978-3-662-46875-3_100856 ◽

2017 ◽

pp. 1636-1636

Keyword(s):

Estrogen Receptor ◽

Progesterone Receptor ◽

Her 2

Download Full-text

Estrogen receptor α and β, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast

Oncology Reports ◽

10.3892/or.12.4.695 ◽

2004 ◽

Author(s):

Achim Rody ◽

Raihanatou Diallo ◽

Christopher Poremba ◽

Regina Speich ◽

Pia Wuelfing ◽

...

Keyword(s):

Estrogen Receptor ◽

Progesterone Receptor ◽

Ductal Carcinoma In Situ ◽

Carcinoma In Situ ◽

Ductal Carcinoma ◽

Estrogen Receptor Α ◽

Her 2

Download Full-text

Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: A pilot study

Pathology - Research and Practice ◽

10.1016/j.prp.2011.01.005 ◽

2011 ◽

Vol 207 (3) ◽

pp. 182-187 ◽

Cited By ~ 4

Author(s):

İbrahim Metin Çiriş ◽

Kemal Kürşat Bozkurt ◽

Şirin Başpinar ◽

Fatma Nilgün Kapucuoğlu

Keyword(s):

Pilot Study ◽

Breast Carcinomas ◽

Her 2 ◽

Cox 2 ◽

Invasive Breast Carcinomas

Download Full-text

A Rare Case of Triple Positive Metachronous Breast Cancer

Journal of Investigative Medicine High Impact Case Reports ◽

10.1177/2324709619892106 ◽

2019 ◽

Vol 7 ◽

pp. 232470961989210

Author(s):

Hardik S. Chhatrala ◽

John Khuu ◽

Lara Zuberi

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Brain Metastasis ◽

Progesterone Receptor ◽

Rare Case ◽

Contralateral Breast Cancer ◽

Contralateral Breast ◽

Her 2 ◽

Metachronous Breast Cancer ◽

Aggressive Clinical Course

Metachronous contralateral breast cancer (MCBC) is defined as contralateral breast cancer (BC) diagnosed more than 1 year after previous BC diagnosis. More BC survivors are at risk of MCBC given improved life expectancy with the availability of advanced cancer care. Estrogen receptor/progesterone receptor negative and HER-2-positive status of first BC are independent risk factors for the development of MCBC. We present a rare case of triple positive (estrogen receptor, progesterone receptor, HER-2 positive) MCBC patient who eventually developed brain metastasis within 15 months despite a near complete pathologic response of primary tumor. This case highlights that even in this era of antiestrogen and anti-HER-2 therapies, triple positive MCBC can have an aggressive clinical course, especially with brain metastasis as the first sign of metastasis.

Download Full-text

Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.517 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. 517-517

Author(s):

M. J. Rodrigues ◽

J. Wassermann ◽

L. Albiges-Sauvin ◽

D. Stevens ◽

E. Brain ◽

...

Keyword(s):

High Risk ◽

Ductal Carcinoma ◽

Significant Risk ◽

Left Ventricular ◽

Left Ventricular Ejection ◽

Breast Carcinomas ◽

Ventricular Ejection Fraction ◽

Node Negative ◽

Her 2 ◽

Invasive Breast Carcinomas

517 Background: Trials have shown benefit of adjuvant trastuzumab (TZM) for node-positive (N+) or supra-centrimetric HER-2+ breast carcinomas. There are limited data concerning infra-centimetric HER-2+ invasive breast carcinomas (InfraHER-2). These tumors are being recognized as a high-risk group among all T1a/b tumors. Methods: Retrospective multicenter series from 2000 to 2008 of infra-centimetric HER-2+ invasive breast carcinomas (InfraHER-2). Tumors with ≥80% of ductal carcinoma in situ, multifocal and metastatic tumors were excluded. Results: 96 cases have been evaluated, 75 were node negative (N- InfraHER-2). All patients had surgery. 57% (n = 43) had a sentinel lymph node procedure. 73% (n = 55) had a local irradiation and 36 a tumor bed boost. Nodal irradiation of internal mammar and infra/supraclavicular regions was done in 20% and 17% respectively. 44% (n = 33) had chemotherapy (CT), almost all (31) were associated to TZM. Anthracycline-based (A), taxane-based (T) and A/T combinations were chosen for 54%, 4% and 42% respectively. One patient developed myocardial infarction after A resulting in heart failure; 2 had a transient left ventricular ejection fraction decrease below 50% after TZM. Decision of adjuvant CT was associated (all p < 0.05) with hormonal receptors (HR) negative status, Elston-Ellis grade (EE) 2/3 and high mitotic index (MI) while patients with HR+/low MI tumors were rarely treated (p < 0.001). 32/39 HR+ patients received hormonotherapy (80%); 21 received aromatase inhibitors, 6 tamoxifen and 5 LHRH agonists. With a 25 months median follow-up, there was no invasive recurrence in TZM treated patients. 3 of the 44 patients treated without TZM nor CT (7%) had local or metastatic recurrence including one fatal; they had initially HR- EE 2/3 T1b tumors. Conclusions: In our practice, decision of TZM-based therapy for InfraHER-2 N- tumors is associated with high-risk profile. Indeed, N- InfraHER-2 tumors may have a significant risk of recurrence which could be avoided by adjuvant TZM. Patients with N- InfraHER-2 tumors should be included in HER-2-targeted adjuvant trials. [Table: see text]

Download Full-text